苯拉唑马布
医学
嗜酸性粒细胞增多症
痰
美波利祖马布
免疫学
哮喘
安慰剂
呼出气一氧化氮
强的松
内科学
胃肠病学
嗜酸性粒细胞
肺活量测定
肺结核
病理
替代医学
作者
Manali Mukherjee,A Bhalla,Carmen Venegas-Garrido,C Huang,K Radford,M Kjarsgaard,Sylvia Lauks,K Son,N Lavigne,R Sehmi,Paul M. O’Byrne,P Nair
出处
期刊:
日期:2022-09-04
卷期号:: 3994-3994
被引量:1
标识
DOI:10.1183/13993003.congress-2022.3994
摘要
Introduction: Targeting the IL-5 ligand does not suppress airway eosinophilia in a subset of severe asthmatics. We investigated if targeting the IL-5 receptor with benralizumab would suppress airway eosinophilia leading to greater asthma control. Methods: Sixteen severe asthmatics (9 females, mean age 58±14 years) on daily high-dose corticosteroid therapy (14 prednisone-dependent, median dose 7.5 mg) with ACQ≥1.5 and sputum eosinophils>3% despite mepolizumab (n=13, 100 mg, subcutaneous) or Reslizumab (n=3, 3mg/kg, intravenous) for ≥6 months were recruited in a sequential placebo-controlled trial (NCT03470311). Clinical outcomes were assessed at baseline (V1), after two months of placebo treatment (V3), and after 5 injections of benralizumab (V10). Results: Benralizumab completely depleted sputum and blood eosinophils in all 16 patients, with clinical improvements in FEV1, and ACQ-5 (Fig1). However, the decrease in fractional exhaled nitric oxide, FeNO (p>0.05) was modest. Despite complete suppression of eosinophilia and mean decrease in asthma control questionnaire (ACQ-5) by 1.21 points, 37% (6/16) patients still documented ACQ >1.5. Conclusions: Targeting IL-5R with benralizumab suppresses sputum and blood eosinophilia that is uncontrolled by anti-IL5 neutralizing antibodies in severe asthmatics. Residual symptoms, associated with raised FeNO may indicate IL-4R activity.
科研通智能强力驱动
Strongly Powered by AbleSci AI